HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW Biologics' TGF-? Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
Angkor Resources Reports University Study Supporting Copper-Molybdenum Porphyry Potential at Andong Bor, Cambodia
VanadiumCorp and Université de Sherbrooke Announce Publication of Peer-Reviewed Research on Lac Doré Vanadiferous Titanomagnetite
